Inovalon allowed Daiichi Sankyo to use its platforms to identify outcomes for abuse-deterrent opioids. Financial details of the deal were not disclosed.
"Do we really wish to have a science-based society or should we let ourselves be governed by prejudices and misconceptions?" ask Roberto Defez, a molecular microbiologist at the Institute of Bioscience and BioResources of the Italian National Research Council, and Dennis Eriksson, a researcher with the Department of Plant Breeding in the Swedish University of Agricultural Sciences. They make the case for learning the facts about biotech crops after an EU court ruled that prejudices regarding these foods are unfounded.
A proposal was published by the UK Department for Transport intended to increase the amount of biofuel in the transportation energy mix and bring about additional changes in the Renewable Transport Fuel Obligation. The Renewable Energy Association welcomed the proposed changes but is unsure that they will help the biofuel industry reach its full potential.
Allergan and Ironwood are promoting Linzess in a TV ad called "Overwhelmed," which shows people obscured by piles of bottles and boxes of medications and is aimed at men and women wanting more relief from their stomach pain and constipation management regimens. The campaign suggests that the need to use so many treatments indicates a more serious condition requiring prescription drugs, said Ironwood Pharmaceuticals' Sharon DeBacco.
Exact Sciences is once again deploying its "Little CG" animated kit to promote the convenience of its Cologuard home colon cancer screenings. Its most recent television ad "No Place Like Home," which debuted Sept. 11, features Little CG talking about inappropriate places to take the test, such as public restrooms and portable toilets, before he finally arrives home.
Ninety-one percent of online patient community members say the platforms help to influence their health care decisions, according to a survey of 433 members by Wego Health. Many patients feel more comfortable sharing information with members with a common condition than on an open forum such as Facebook, said MyHealthTeams CEO Eric Peacock.
A $24.3 million expanded contract option related to a contract with the HHS' Biomedical Advanced Research and Development Authority was executed by UK-based Avita Medical, extending the company's Project Bioshield contract through September 2022. The company, which intends to use the money for the development and procurement of its ReCell devices, could obtain up to $37 million if certain options of the contract are executed for funding clinical studies and postmarket surveillance.
Lightstone Ventures raised $250 million for Lightstone Ventures II, its fund that aims to make investments ranging from $15 million to $20 million per transaction in around 15 early-stage medical device and biotech companies.
A round of equity financing could pull in $15 million for Ra Medical, according to a filing with the SEC. The company, which already raised $650,000 from three unnamed investors in the round, did not disclose how it intends to use the proceeds.